French company Enterome Bioscience has signed an exclusive worldwide license agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop and commercialize novel small molecule FimH antagonists to treat inflammatory bowel diseases (IBD).
Enterome, which specializes in the development of pharmaceuticals and diagnostics based on the gut microbiome, plans to take EB 8018, the lead compound in this program, into first human clinical trials this year, as well as a companion diagnostic to identify patients with inflammatory bowel diseases (IBD) who will benefit from their use.
Through application of its metagenomics platform, Enterome has identified a key bacterial species – adherent-invasive Escherichia coli (AIEC) – which is responsible for triggering inflammation in IBD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze